Patents by Inventor Christopher Carl Frye
Christopher Carl Frye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230279134Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.Type: ApplicationFiled: November 1, 2022Publication date: September 7, 2023Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
-
Patent number: 11512134Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.Type: GrantFiled: January 23, 2020Date of Patent: November 29, 2022Assignee: ELI LILLY AND COMPANYInventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
-
Publication number: 20220356229Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: March 4, 2021Publication date: November 10, 2022Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Patent number: 11447541Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: June 22, 2021Date of Patent: September 20, 2022Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Publication number: 20220251172Abstract: Mammalian cell lines with reduced expression and/or activity of lipases/esterases, and methods of producing the same are provided. Also provided are compositions comprising polysorbate and recombinant proteins produced in said mammalian cells which have improved polysorbate stability.Type: ApplicationFiled: April 14, 2022Publication date: August 11, 2022Inventors: Christopher Carl FRYE, Troii HALL, Lihua HUANG, Stephanie Lynn SANDEFUR
-
Patent number: 11370828Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: June 22, 2021Date of Patent: June 28, 2022Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Publication number: 20210388066Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: June 22, 2021Publication date: December 16, 2021Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Publication number: 20210292393Abstract: Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: ApplicationFiled: December 9, 2020Publication date: September 23, 2021Applicants: AbCellera Biologics Inc., The United States of America, as represented by the Secretary, Department of Health and Hunman ServiInventors: Kathryn WESTENDORF, Stefanie ZENTELIS, Krithika MUTHURAMAN, Kevin JEPSON, Ester FALCONER, John MASCOLA, Barney GRAHAM, Kizzmekia CORBETT, Julie LEDGERWOOD, Lingshu WANG, Olubukola ABIONA, Wei SHI, Wing-pui KONG, Yi ZHANG, Bryan Edward JONES, Denisa FOSTER, Julian DAVIES, Qing CHAI, Christopher Carl FRYE, Ganapathy GOPALRATHNAM, Jörg HENDLE, John Michael SAUDER, Jeffrey Streetman BOYLES, Anna PUSTILNIK
-
Patent number: 10906983Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and is useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.Type: GrantFiled: July 25, 2018Date of Patent: February 2, 2021Assignee: ELI LILLY AND COMPANYInventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
-
Publication number: 20200377607Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.Type: ApplicationFiled: July 25, 2018Publication date: December 3, 2020Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
-
Publication number: 20200157234Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.Type: ApplicationFiled: January 23, 2020Publication date: May 21, 2020Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
-
Patent number: 7655627Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: GrantFiled: December 7, 2005Date of Patent: February 2, 2010Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Patent number: 7622445Abstract: The present invention relates to novel muteins of human fibroblast growth factor-21 with reduced susceptibility for proteolytic degradation when expressed in yeast. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: GrantFiled: August 25, 2005Date of Patent: November 24, 2009Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Patent number: 7582607Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: GrantFiled: July 26, 2005Date of Patent: September 1, 2009Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Publication number: 20090118190Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.Type: ApplicationFiled: January 6, 2009Publication date: May 7, 2009Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
-
Patent number: 7491697Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.Type: GrantFiled: December 1, 2004Date of Patent: February 17, 2009Assignee: Eli Lilly and CompanyInventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
-
Publication number: 20080103096Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.Type: ApplicationFiled: July 26, 2005Publication date: May 1, 2008Applicant: ELI LILLY AND COMPANYInventors: Christopher Carl Frye, Lihua Huang, Radmila Micanovic
-
Patent number: 6136565Abstract: The present invention relates to recombinant hemoglobin solutions containing reduced amounts of protoporphyrin IX and to methods of producing such hemoglobin solutions. The methods are accomplished by overexpressing the hemH gene in a suitable host cell or by increasing the production of hemH in a host cell, for example, by integration of the hemH gene into the chromosome of the host cell or by inserting multiple copies of the gene in host cells naturally having a hemH gene.Type: GrantFiled: October 18, 1999Date of Patent: October 24, 2000Assignees: Baxter Biotech Technology Sarl, Eli Lilly and CompanyInventors: Elaine A. Best, Charles Lee Hershberger, Christopher Carl Frye
-
Patent number: 6027911Abstract: The present invention provides the cDNA sequence encoding bovine dipeptidylaminopeptidase 1. The invention demonstrates that bovine DAP 1 coded by a single cDNA. The mature protein is derived from a single polypeptide consisting of a signal peptide, and a major polypeptide which is processed to generate the a subunit, b subunit and g subunit.Type: GrantFiled: April 3, 1998Date of Patent: February 22, 2000Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Charles Lee Hershberger, Haichao Zhang
-
Patent number: 6008041Abstract: The present invention provides the cDNA sequence encoding bovine dipeptidylaminopeptidase 1. The invention demonstrates that bovine DAP 1 coded by a single cDNA. The mature protein is derived from a single polypeptide consisting of a signal peptide, and a major polypeptide which is processed to generate the a subunit, b subunit and g subunit.Type: GrantFiled: May 2, 1997Date of Patent: December 28, 1999Assignee: Eli Lilly and CompanyInventors: Christopher Carl Frye, Charles Lee Hershberger, Haichao Zhang